Table: Towa Pharmaceutical -2023/24 parent results
May 14 (Reuters)-
Towa Pharmaceutical Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2024 Mar 31, 2023 Mar 31, 2025 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 149.22 124.00
(+20.3 pct) (+0.6 pct)
Operating 19.96 9.31
(+114.5 pct) (-50.3 pct)
Recurring 27.23 8.54
(+218.8 pct) (-62.0 pct)
Net 19.60 6.33
(+209.6 pct) (-61.2 pct)
EPS 398.21 yen 128.60 yen
Ann Div 60.00 yen 60.00 yen 60.00 yen
-Q2 Div 30.00 yen 30.00 yen 30.00 yen
-Q4 Div 30.00 yen 30.00 yen 30.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results